|
|
|
시장보고서
Therapeutics for Memory and Cognition Disorders
|
Abstract
This Report:
- Details the disease states that lead to memory & cognition impairment
- Provides forecasts and detail relative to the products available to treat
this condition.
- Provides definition and market structure, including discussion on
cognition and diagnostic tests
- Analyzes market size and key players
- Identifies worldwide industry structure, including growth drivers and
obstacles, and related technology considerations
- Details primary and secondary applications, legislation and the regulatory
environment, related deals, and partnerships, patent analysis, and company
profiles.
- Analyzes the market outlook, trends, and challenges.
Table of Contents
Chapter-1: SUMMARY 6
- SUMMARY TABLE WORLDWIDE POTENTIAL MARKET FOR MEMORY/COGNITION
THERAPEUTICS, BY DISEASE AREA, THROUGH 2014 ($ MILLIONS) 4
- SUMMARY FIGURE WORLDWIDE MEMORY/COGNITION THERAPEUTICS MARKET, BY DISEASE
AREA, 2008 (%) 5
- DISEASE STATES 6
- DISEASE STATES (CONTINUED) 7
- TREATMENTS IN DEVELOPMENT 8
- THE FUTURE 9
Chapter-2: OVERVIEW 10
- PRIMARY 20
- TABLE 3 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%) 20
- FIGURE 1 DEMENTIA CASES BY UNDERLYING DISEASE STATE (%) 21
- SECONDARY 22
- MEDICATION-RELATED 22
- SUBSTANCE ABUSE 23
- CREUTZFELDT JAKOB DISEASE 23
- Creutzfeldt Jakob Disease (Continued) 24
- ADHD 25
- MULTIPLE SCLEROSIS 25
- Multiple Sclerosis (Continued) 26
- INFECTION 27
- METABOLIC DISORDERS 27
- BRAIN TUMORS 28
- CABG 28
- TABLE 4 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 28
- PRIMARY 28
- ALZHEIMER' S DISEASE 28
- TABLE 5 WORLDWIDE DISEASE PREVALENCE: ALZHEIMER' S DISEASE (%) 29
- TABLE 6 EXISTING TREATMENTS: ALZHEIMER' S DISEASE 29
- Role of the Cholinergic System 29
- Role of Beta-Amyloid Protein 30
- TABLE 7 TREATMENT FORECAST FOR ALZHEIMER' S DISEASE, THROUGH 2014 ($
MILLIONS) 31
- FIGURE 2 TREATMENT FORECAST FOR ALZHEIMER' S DISEASE, 2007-2014 ($
MILLIONS) 31
- VASCULAR DEMENTIA 32
- TABLE 8 WORLDWIDE DISEASE PREVALENCE: VASCULAR DEMENTIA (%) 32
- TABLE 9 EXISTING TREATMENTS: VASCULAR DEMENTIA 32
- Cause 33
- VCIND 34
- Binswanger' s Disease 34
- Multi-Infarct Dementia 34
- Treatment 35
- TABLE 10 TREATMENT FORECAST FOR VASCULAR DEMENTIA, THROUGH 2014 ($
MILLIONS) 35
- FIGURE 3 TREATMENT FORECAST FOR VASCULAR DEMENTIA, 2007-2014 ($ MILLIONS)
36
- Counseling and Psychotherapy 37
- Pharmacotherapy 37
- Outlook 38
- LEWY BODY DEMENTIA 38
- TABLE 11 WORLDWIDE DISEASE PREVALENCE: LEWY BODY DEMENTIA (%) 39
- Treatment 39
- TABLE 12 EXISTING TREATMENTS: LBD 40
- Outlook 40
- TABLE 13 TREATMENT FORECAST FOR LBD, THROUGH 2014 ($ MILLIONS) 40
- FIGURE 4 TREATMENT FORECAST FOR LBD, 2007-2014 ($ MILLIONS) 41
- PARKINSON' S DISEASE 41
- Parkinson' s Disease (Continued) 42
- Other Parkinsonism Syndromes 43
- Recognizing Other Causes of Parkinsonism 43
- Medication-Induced Parkinsonism 44
- Corticobasal Degeneration (CBD) 44
- Multiple System Atrophy (MSA) 44
- Multiple System Atrophy (Continued) 45
- Multiple System Atrophy (Continued) 46
- SCHIZOPHRENIA 47
- Schizophrenia (Continued) 48
- Schizophrenia (Continued) 49
- TABLE 14 WORLDWIDE DISEASE PREVALENCE: SCHIZOPHRENIA (%) 50
- Treatment 50
- TABLE 15 EXISTING TREATMENTS: SCHIZOPHRENIA 51
- TABLE 16 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS),
THROUGH 2014 ($ MILLIONS) 51
- FIGURE 5 TREATMENT FORECAST FOR COGNITION IN SCHIZOPHRENIA (CIAS),
2007-2014 ($ MILLIONS) 52
- Treatment (Continued) 53
- Outlook 54
- MCI/AAMI 54
- TABLE 17 WORLDWIDE DISEASE PREVALENCE: MCI/AAMI (%) 55
- TABLE 18 EXISTING TREATMENTS: MCI/AAMI 55
- TABLE 19 TREATMENT FORECAST FOR MCI/AAMI, THROUGH 2014 ($ MILLIONS) 55
- FIGURE 6 TREATMENT FORECAST FOR MCI/AAMI, 2007-2014 ($ MILLIONS) 56
- HUNTINGTON' S DISEASE 56
- Demographics 57
- TABLE 20 WORLDWIDE DISEASE PREVALENCE: HUNTINGTON' S DISEASE (%) 57
- TABLE 21 EXISTING TREATMENTS: HUNTINGTON' S DISEASE 57
- Demographics (Continued) 58
- Treatment 59
- TABLE 22 TREATMENT FORECAST FOR HUNTINGTON' S DISEASE, THROUGH 2014 ($
MILLIONS) 60
- FIGURE 7 TREATMENT FORECAST FOR HUNTINGTON' S DISEASE, 2007-2014 ($
MILLIONS) 61
- HIV-RELATED MEMORY AND COGNITION EFFECTS 61
- TABLE 23 WORLDWIDE DISEASE PREVALENCE: HIV-RELATED (%) 62
- TABLE 24 EXISTING TREATMENTS: HIV-RELATED 63
- TABLE 25 TREATMENT FORECAST FOR HIV-RELATED, THROUGH 2014 ($ MILLIONS) 63
- FIGURE 8 TREATMENT FORECAST FOR HIV-RELATED, 2007-2014 ($ MILLIONS) 64
- GENETIC DISEASES 64
- TABLE 26 WORLDWIDE DISEASE PREVALENCE: GENETIC DISEASES (%) 64
- TABLE 27 EXISTING TREATMENTS: GENETIC DISEASES 65
- TABLE 28 TREATMENT FORECAST FOR GENETIC DISEASES: COGNITION ONLY,
THROUGH 2014 ($ MILLION) 65
- FIGURE 9 TREATMENT FORECAST FOR GENETIC DISEASES, 2007-2014 ($ MILLIONS)
66
- Pick' s Disease 66
- Krabbe Disease 67
- Krabbe Disease (Continued) 68
Chapter-3: APPLICATIONS 49
Chapter-4: MECHANISMS OF ACTION 31
- MECHANISMS OF ACTION 69
- TABLE 29 MARKETED TREATMENTS: ALL DISEASES 70
- COMMON MECHANISMS 71
- CHOLINESTERASE INHIBITORS 71
- TABLE 30 CHOLINESTERASE INHIBITORS 71
- NMDA Antagonists 71
- TABLE 31 NMDA ANTAGONISTS 72
- Nicotinics 72
- TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS 73
- Calcineurins 73
- TABLE 33 CALCINEURINS 73
- GABA Modulators 74
- TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS 74
- Hormones 75
- TABLE 35 HORMONES 75
- OTHER MECHANISMS 75
- COGNITION ENHANCERS IN DEVELOPMENT 76
- DRUGS FOR DISEASE MODIFICATION 76
- Secretase Inhibitors 76
- Metal Chelation 76
- Vaccines 76
- Statins 76
- Neurotransmitter Targets 77
- NSAIDS 77
- Antioxidants 77
- Hormones 78
- Other Agents 78
- TABLE 36 OVERVIEW OF MEMORY/COGNITION TREATMENTS 78
- TABLE 36 (CONTINUED) 79
- TABLE 37 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS, BY DEVELOPMENT
STATUS 79
- TABLE 37 (CONTINUED) 80
- TABLE 37 (CONTINUED) 81
- TABLE 37 (CONTINUED) 82
- TABLE 37 (CONTINUED) 83
- TABLE 37 (CONTINUED) 84
- TABLE 37 (CONTINUED) 85
- FIGURE 10 DEVELOPMENT PIPELINE OF MEMORY/COGNITION DRUGS: NUMBER OF
PROGRAMS AT EACH CLINICAL STAGE 85
- Glutamate 86
- Calcium Channels 86
- Maxi-K Channels 86
- CREB and Phosphodiesterase 87
- Acetylcholine 87
- Dopamine 87
- Serotonin 88
- GABA 88
- The Cannabinoid System 88
- Histamine 89
- Neurohormones and Neuropeptides 89
- Other Molecular Targets 89
- Genome and Stem Cells 90
- FUTURE COGNITION ENHANCERS 91
- Changes in Society 91
- Increasing Knowledge 91
- Scientific Limitations 92
- Implications 93
- Potential Benefits and Harms 93
- Health Economics 94
- Regulation, Ethics, and Society 94
- TABLE 38 OTC TREATMENTS/NATURAL PRODUCTS 95
- OTC TREATMENTS 96
- Ginkgo 97
- GENE THERAPY 98
- STIMULANTS 98
- Stimulants (Continued) 99
Chapter-5: WORLDWIDE INDUSTRY STRUCTURE 24
- GROWTH DRIVERS 100
- TABLE 39 TOP-SELLING MEMORY AND COGNITION DRUGS ($ MILLIONS) 100
- AGING POPULATION 100
- Aging Population (Continued) 101
- OFF-LABEL USE 102
- UNDERSTANDING OF MECHANISMS 103
- Transcranial Magnetic Stimulation 104
- Genetic Modifications 105
- GROWTH OBSTACLES 105
- UNDERSTANDING OF MECHANISMS 106
- TABLE 40 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106
- FIGURE 11 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 106
- CO-MORBID DISEASE STATES 107
- ACCEPTANCE OF MEMORY AND COGNITION AS TREATABLE CONDITIONS 107
- TREATMENT OF CHILDREN 107
- Treatment of Children (Continued) 108
- KEY COMPETITIVE FACTORS 109
- PRODUCT LAUNCH 109
- LIFE CYCLE MANAGEMENT 109
- INDUSTRY LEADERS 110
- MERCK 110
- TABLE 41 MERCK MEMORY AND COGNITION PIPELINE 110
- ROCHE 110
- TABLE 42 ROCHE MEMORY AND COGNITION PIPELINE 110
- PFIZER 111
- TABLE 43 PFIZER MEMORY AND COGNITION PIPELINE 111
- SHIRE 111
- TABLE 44 SHIRE MEMORY AND COGNITION PIPELINE 111
- CEPHALON 112
- TABLE 45 CEPHALON MEMORY AND COGNITION PIPELINE 112
- PAYORS 112
- PAYORS (CONTINUED) 113
- INTERNATIONAL ASPECTS 114
- TABLE 46 PER CAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY,
THROUGH 2006 ($ MILLIONS) 115
- BIOTECHNOLOGY CLUSTERS 116
- LEGISLATION AND REGULATORY ENVIRONMENT 116
- VALIDATED TARGETS 116
- LACK OF BIOMARKERS 116
- TRANSLATIONAL MEDICINE 117
- REIMBURSEMENT 118
- SCHEDULING STATUS 119
- MEMORY AND COGNITION AS A STAND-ALONE INDICATION 119
- RELATED DEALS AND PARTNERSHIPS 119
- RELATED DEALS AND PARTNERSHIPS (CONTINUED) 120
- TABLE 47 RELATED DEALS AND PARTNERSHIPS, 2002-2008 121
- TABLE 47 (CONTINUED) 122
- TABLE 47 (CONTINUED) 123
Chapter-6: PATENT ANALYSIS 19
- INTRODUCTION 124
- TRENDS BY COUNTRY 124
- TABLE 48 PATENT ANALYSIS MAJOR U.S. PATENT HOLDERS IN MEMORY/COGNITION
DISORDERS 124
- FIGURE 12 MAJOR PATENT HOLDERS BY ASSIGNEE (%) 125
- TRENDS BY ASSIGNEE 125
- TRENDS BY TECHNOLOGY 126
- TABLE 49 U.S. PATENT APPLICATIONS 127
- TABLE 49 (CONTINUED) 128
- TABLE 49 (CONTINUED) 129
- TABLE 49 (CONTINUED) 130
- TABLE 49 (CONTINUED) 131
- TABLE 49 (CONTINUED) 132
- TABLE 49 (CONTINUED) 133
- TABLE 49 (CONTINUED) 134
- TABLE 50 U.S. PATENTS GRANTED 135
- TABLE 50 (CONTINUED) 136
- TABLE 50 (CONTINUED) 137
- TABLE 50 (CONTINUED) 138
- TABLE 50 (CONTINUED) 139
- TABLE 50 (CONTINUED) 140
- TABLE 50 (CONTINUED) 141
- TABLE 50 (CONTINUED) 142
Chapter-7: OUTLOOK: TRENDS AND CHALLENGES 4
- GENERAL TRENDS 143
- GENERAL TRENDS (CONTINUED) 144
- ETHICAL IMPLICATIONS 145
- ETHICAL IMPLICATIONS (CONTINUED) 146
Chapter-8: COMPANY PROFILES 11
- ACADIA PHARMACEUTICALS 147
- ACCERA, INC. 147
- ACUMEN PHARMACEUTICALS 147
- ALLON THERAPEUTICS (FKA NEURODISCOVERY) 147
- ALZHYME PTY 148
- AMARIN PHARMACEUTICALS 148
- ASTRAZENECA 148
- BRAINCELLS, INC. 149
- COGNITION PHARMACEUTICALS 149
- COLUCID PHARMACEUTICALS 149
- COMENTIS 149
- CORTEX PHARMACEUTICALS 150
- ENVIVO PHARMACEUTICALS 150
- GALENEA 150
- GLAXOSMITH KLINE 151
- HELICON THERAPEUTICS 151
- INTELLECT NEUROSCIENCES 151
- INTRA-CELLULAR THERAPIES 151
- IPSEN 152
- LEXICON PHARMACEUTICALS 152
- MEDIVATION 152
- MEMORY PHARMACEUTICALS 152
- MERCK 153
- MERCKSERONO 153
- MITHRIDION 153
- NEUREN PHARMACEUTICALS 153
- NEUROSEARCH 153
- NEURO-HITECH 154
- NEWRON PHARMACEUTICALS 154
- NOVARTIS 154
- PFIZER 154
- PRANA BIOTECHNOLOGY 155
- PSYCHOGENICS 155
- SANOFI-AVENTIS 155
- SATORI PHARMACEUTICALS 155
- SCIELE PHARMA 155
- SEASIDE THERAPEUTICS 156
- SHIRE 156
- TAKEDA 156
- TARGACEPT 156
- TAURX THERAPEUTICS 156
- TEVA PHARMACEUTICALS 157
- VOYAGER PHARMACEUTICAL / DURAMED 157
- WYETH 157
Chapter-9: APPENDIX 11
- COMPANY LISTING 158
- ACADIA PHARMACEUTICALS, INC. 158
- ACCERA, INC. 158
- ACUMEN PHARMACEUTICALS, INC. 158
- ALLON THERAPEUTICS, INC. 159
- ALZHYME, LTD. 159
- AMARIN CORP PLC. 159
- AMARIN PHARMA INC. 159
- ASTRAZENECA 160
- BRAINCELLS, INC. 160
- COGNITION PHARMACEUTICALS LLC 160
- COGNITIVE PHARMACEUTICALS LTD 160
- COLUCID PHARMACEUTICALS 160
- COMENTIS (FKA ATHENAGEN) 160
- CORTEX PHARMACEUTICALS, INC. 15231 BARRANCA PARKWAY 161
- ENVIVO PHARMACEUTICALS 161
- GALENEA CORP. 161
- GLAXOSMITHKLINE 161
- HELICON THERAPEUTICS, INC. 161
- INTELLECT NEUROSCIENCES, INC. 162
- INTRA-CELLULAR THERAPIES 162
- IPSEN 162
- LEXICON PHARMACEUTICALS 162
- MEDIVATION, INC. 163
- MEMORY PHARMACEUTICALS 163
- MERCK & CO., INC. 163
- MERCKSERONO 163
- MITHRIDION 163
- NEUREN PHARMACEUTICALS, LTD 164
- NEUROSEARCH A/S 164
- NEURO-HITECH, INC. 164
- NEWRON 164
- NOVARTIS 165
- PFIZER 165
- PRANA 165
- PSYCHOGENICS, INC. 165
- SANOFI-AVENTIS 165
- SATORI PHARMACEUTICALS 165
- SCIELE PHARMA 166
- SEASIDE THERAPEUTICS 166
- SHIRE 166
- TAKEDA 166
- TARGACEPT, INC. 167
- TAURX THERAPEUTICS LTD. 167
- TEVA PHARMACEUTICALS 167
- VOYAGER PHARMACEUTICALS 167
- WYETH PHARMACEUTICALS 167
- Wyeth Pharmaceuticals (Continued) 168
|
 |
